New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

Ofatumumab is one of the three anti-CD20 monoclonal antibodies currently available for the treatment of chronic lymphocytic leukemia (CLL). The US Food and Drug Administration (FDA) approved the use of ofatumumab in patients with CLL refractory to fludarabine and alemtuzumab in 2009, and the Europea...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Laurenti, Luca, Innocenti, Idanna, Autore, Francesco, Sica, Simona, Efremov, Dimitar G
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2016
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4725726/
https://ncbi.nlm.nih.gov/pubmed/26855591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S72845
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky